ArticleDiscover oncology2025
Genetically predicted inflammatory protein mediate the association between lipidome and colon cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrevious studies show correlations between colon cancer, dyslipidemia, and inflammatory proteins. However, the exact causal relationships are still unclear and no comprehensive analysis exists.
methodsWe used a two-sample Mendelian Randomization (MR) strategy to assess the link between lipidomes and colon cancer risk. Bayesian Weighted Mendelian Randomization (BWMR) and MR-robust adjusted profile score (MR-RAPS) were employed to validate our findings. Furthermore, inverse MR analysis was conducted to investigate the possibility of reverse causation. Through a comprehensive two-step MR analysis, we identified the mediating effect of inflammatory factors. Various sensitivity analyses were carried out to ensure the reliability and robustness of our results.
resultsOur MR analysis highlighted negative correlations between Phosphatidylcholine (O-16:1_18:0) (OR, 95% CI 0.771, (0.610, 0.975)), Phosphatidylethanolamine (O-16:1_22:5) (OR, 95% CI 0.788, (0.664, 0.934)), Phosphatidylethanolamine (O-18:1_18:2) (OR, 95% CI 0.825, (0.708, 0.960)) and colon cancer. In contrast, we found positive correlations with Sterol ester (27:1/18:3) (OR, 95% CI 1.278, (1.068, 1.530)), Phosphatidylcholine (18:0_22:5) (OR, 95% CI 1.322, (1.118, 1.563)), Triacylglycerol (46:1) (OR, 95% CI 1.272, (1.047, 1.546)), Triacylglycerol (46:2) (OR, 95% CI 1.236, (1.034, 1.478)) and colon cancer. Furthermore, mediation analysis revealed that a fraction of the impacts of Phosphatidylcholine (18:0_22:5) and Phosphatidylethanolamine (O-16:1_22:5) on colon cancer were mediated by TNF-related apoptosis-inducing ligand levels.
conclusionThis study presents evidence supporting potential causal correlations between 7 lipidome levels and colon cancer, based on Mendelian randomization analyses. Additionally, inflammatory factors mediate some of these effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.